Filing Details
- Accession Number:
- 0001177648-18-000022
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-04-18 17:34:59
- Reporting Period:
- 2018-04-16
- Accepted Time:
- 2018-04-18 17:34:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1177648 | Enanta Pharmaceuticals Inc | ENTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1646976 | Nathalie Adda | C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472 | Sr. Vp & Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-04-16 | 2,955 | $43.46 | 10,225 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-04-16 | 1,800 | $85.11 | 8,425 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-04-16 | 2,425 | $85.92 | 6,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2018-04-16 | 2,955 | $0.00 | 2,955 | $43.46 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
87,045 | 2025-06-29 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.45, inclusive.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.47 to $86.45, inclusive.
- The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date.